학술논문
Dissection of PIK3CA Aberration for Cervical Adenocarcinoma Outcomes
Document Type
article
Author
Tony K. H. Chung; Graeme Doran; Tak-Hong Cheung; So-Fan Yim; Mei-Yung Yu; Michael J. Worley; Kevin M. Elias; Aaron R. Thorner; Chandra Sekhar Pedamallu; Akinyemi I. Ojesina; Kei-Man Lau; Matthew D. Ducar; Raymond R. Y. Wong; Vivian W. Wang; Anwesha Nag; Bruce M. Wollison; Audrey Dalgarno; Jacqueline H. S. Lee; Suet-Ying Yeung; Lo Wong; Neil S. Horowitz; Michelle R. Davis; Shuk-On A. Leung; Yi Mu; Samuel C. Mok; Paul K. S. Chan; Michael S. Lawrence; Christopher P. Crum; Rossa W. K. Chiu; Ross S. Berkowitz; Yick-Fu Wong
Source
Cancers, Vol 13, Iss 13, p 3218 (2021)
Subject
Language
English
ISSN
2072-6694
Abstract
Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in PIK3CA E542K, E545K, or H1047R were detected in 41.7% of tumors. PIK3CA mutation detected in the patient’s circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. PIK3CA mutation in the circulating DNA during follow-up after treatment predicted recurrence with 100% sensitivity and 64.29% specificity. It is the first indication of the predictive power of PIK3CA mutations in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for follow up surveillance and a possibility of tailoring management of this particular women’s cancer.